TRAW

Insider Trades

Name	Value	Action	Price	Current Price
Savchuk NikolayDirector, 10 Percent Owner, Officer: Chief Operating Officer $96396.3k shares BuyDec 29, 2024 $0.01 --
Savchuk NikolayDirector, 10 Percent Owner, Officer: Chief Operating Officer $1.3M96.3k shares BuyDec 29, 2024 $13.42 --
Tpav, LLC10 Percent Owner $1.3M96.3k shares BuyDec 29, 2024 $13.42 --
Tpav, LLC10 Percent Owner $96396.3k shares BuyDec 29, 2024 $0.01 --
Cautreels WernerDirector, Officer: Chief Executive Officer $96396.3k shares BuyDec 29, 2024 $0.01 --
Cautreels WernerDirector, Officer: Chief Executive Officer $1.3M96.3k shares BuyDec 29, 2024 $13.42 --

News

globenewswire.comTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaksglobenewswire.comMay 27

globenewswire.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial Resultsglobenewswire.comMay 15

benzinga.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreakbenzinga.comMay 8

globenewswire.comTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infectionsglobenewswire.comMay 8

zacks.comTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?zacks.comApr 20

Trade TRAW

About Traws Pharma, Inc.

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

CEO: Iain D. Dukes
IPO Date: Jul 25, 2013

Market Data

Open: $1.30
High: $1.31
Low: $1.22
Volume: 442.8K
52W High: $3.27
52W Low: $1.00

Valuation

Market Cap: $11M
Enterprise Value: $8.3M

Financials

Free Cash Flow: $-21M
Revenue: $2.8M
Net Income: $9.2M
Cash: $3.8M
Debt: $0

Events

EarningsAug 13

EPS est. -0.805